{Reference Type}: Journal Article
{Title}: [The treatment of mucormycosis (zygomycosis) in the 21st century].
{Author}: Ruiz Camps I;Salavert Lletí M;
{Journal}: Rev Iberoam Micol
{Volume}: 35
{Issue}: 4
{Year}: Oct 2018 0
{Factor}: 1.385
{DOI}: 10.1016/j.riam.2018.09.001
{Abstract}: Infections due to zygomycetes, caused by mucorales and entomophthorales, are characterized by angioinvasion and invasion of neighboring organs or structures. Mucorales most commonly cause rhinocerebral, pulmonary, cutaneous or disseminated infection and its spread is favored by several diseases (such as diabetes or chronic kidney disease) and risk factors (neutropenia, immunosuppression, iron overload). They have a high mortality rate, and the key to success in their treatment are early diagnosis, prompt administration of antifungal treatment, and extensive surgical debridement. Currently, isavuconazole constitutes an option for the treatment of those mucormycosis refractory to liposomal amphotericin B. Due to its pharmacokinetic and pharmacodynamic characteristics and its low toxicity, it is also the best choice for maintenance therapy.